TCGA-XF-AAN2-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 61.39947438
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.750
- INTERFERON_GAMMA_RESPONSE+0.590
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.550
- MYC_TARGETS_V1+0.540
- PROTEIN_SECRETION+0.490
- MYC_TARGETS_V2+0.480
- MITOTIC_SPINDLE+0.420
- MTORC1_SIGNALING+0.390
- PI3K_AKT_MTOR_SIGNALING+0.360
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- MYOGENESIS-0.360
- HEDGEHOG_SIGNALING-0.270
- KRAS_SIGNALING_DN-0.270
- BILE_ACID_METABOLISM-0.200
- NOTCH_SIGNALING-0.200
- COAGULATION-0.190
- PANCREAS_BETA_CELLS-0.180
- ANGIOGENESIS-0.160
- APICAL_JUNCTION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-4Z-AA81-01A-11R-A39I-07 | — | — | 0.889 |
| 2 | SRR650153 | — | — | 0.887 |
| 3 | TCGA-78-7542-01A-21R-2066-07 | — | cohortA1 | 0.886 |
| 4 | TCGA-G2-A2EJ-01A-11R-A180-07 | — | — | 0.885 |
| 5 | TCGA-E7-A7XN-01A-11R-A352-07 | — | — | 0.885 |
| 6 | R427 | — | — | 0.884 |
| 7 | TCGA-52-7812-01A-11R-2125-07 | — | cohortA1 | 0.878 |
| 8 | TCGA-CQ-6220-01A-11R-1915-07 | — | — | 0.869 |
| 9 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.869 |
| 10 | R190 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.750 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.420 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |